Preview Mode Links will not work in preview mode

Mar 26, 2020

A special video supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Dr Daniel A Pollyea.

  • Choice of first-line therapy for acute myeloid leukemia (AML); selection of patients who are fit for intensive...


Mar 26, 2020

A special video supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Dr Richard M Stone.

  • Design and results of the QUAZAR AML-001 maintenance trial assessing CC-486 versus placebo for patients with AML...


Mar 24, 2020

Proceedings from a CME symposium held during the 61st ASH Annual Meeting. Featuring perspectives from Drs Mark Levis, Daniel A Pollyea, Richard M Stone and Andrew H Wei.

  • Introduction
    • Program Overview: Dr Neil Love (00:00)
  • Evolving Paradigms in Up-Front Treatment for Older Patients or Those Ineligible for...


Mar 16, 2020

Proceedings from a roundtable discussion with Drs Courtney D DiNardo, Keith W Pratz, Richard M Stone and a group of 20 general medical oncologists and nurse practitioners on the optimal management of acute myeloid leukemia within a community-based setting.

  • Initial Workup and Determination of Eligibility for Intensive...


Feb 26, 2020

Acute Leukemias Update, Issue 1, 2020 — Part 1: Our interview with Dr Perl highlights the following topics as well as cases from his practice:

  • Case: A woman in her early 70s with a history of triple-negative breast cancer receives venetoclax/azacitidine for secondary acute myeloid leukemia (AML) (00:00)
  • Nonspecific...